248 related articles for article (PubMed ID: 17589567)
1. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Harris RE; Beebe-Donk J; Alshafie GA
Int J Biol Sci; 2007 Jun; 3(5):328-34. PubMed ID: 17589567
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Bardou M; Barkun AN; Ghosn J; Hudson M; Rahme E
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):880-7. PubMed ID: 15476151
[TBL] [Abstract][Full Text] [Related]
3. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
4. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.
Harris RE; Beebe-Donk J; Alshafie GA
BMC Cancer; 2006 Jan; 6():27. PubMed ID: 16445867
[TBL] [Abstract][Full Text] [Related]
5. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
7. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Harris RE; Beebe-Donk J; Alshafie GA
Subcell Biochem; 2007; 42():193-212. PubMed ID: 17612052
[TBL] [Abstract][Full Text] [Related]
8. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
9. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
10. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
11. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
[TBL] [Abstract][Full Text] [Related]
12. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Harris RE; Beebe-Donk J; Alshafie GA
BMC Cancer; 2008 Aug; 8():237. PubMed ID: 18702823
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers.
Harris RE; Beebe-Donk J; Schuller HM
Oncol Rep; 2002; 9(4):693-5. PubMed ID: 12066194
[TBL] [Abstract][Full Text] [Related]
14. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
15. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Harley C; Wagner S
Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
[TBL] [Abstract][Full Text] [Related]
18. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
19. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
20. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Zhao SZ; Wentworth C; Burke TA; Makuch RW
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
